Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | AdV-Flt3L + AdV-HSV1-TK + Valganciclovir |
| Synonyms | |
| Therapy Description | |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| AdV-Flt3L | Ad-hCMV-Flt3L | AdV-Flt3L is an adenoviral vector expressing Flt3L, which potentially induces antitumor immune response (PMID: 37657463). | ||
| AdV-HSV1-TK | Ad-hCMV-TK | AdV-HSV1-TK is an adenoviral vector expressing human simplex virus 1 thymidine kinase (HSV1-TK), which potentially induces antitumor immune response (PMID: 37657463). | ||
| Valganciclovir | Valcyte |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT06914479 | Phase I | AdV-Flt3L + AdV-HSV1-TK + Valganciclovir | Virus-Based Gene Therapy (AdV-HSV1-TK and AdV-Flt3L) in Combination With Valacyclovir for the Treatment of Pediatric and Young Adult Patients With Resectable, Recurrent Primary Malignant Brain Tumors | Not yet recruiting | USA | 0 |